Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
POEMS demonstrated that adding goserelin to cyclophosphamide-containing adjuvant chemotherapy significantly reduced premature ovarian failure and increased pregnancy rates in premenopausal women with HR-negative early breast cancer — without compromising disease outcomes. This trial was pivotal in establishing GnRH agonist coadministration during chemotherapy as standard practice for ovarian protection.
Key Result: Ovarian failure at 2 years — 8% (goserelin) vs 22% (chemo alone), OR 0.30 (95% CI 0.09–0.97; two-sided P=0.04)
Safety Signal: Grade ≥2 hormonal toxic effects significantly higher with goserelin (48% vs 24%; P<0.001), but grade ≥3 rates were comparable (7% vs 5%; P=0.89).
✅ Patient Eligibility
Must Have:
- ER-negative and PR-negative breast cancer
- Operable stage I to IIIA
- Premenopausal, age 18–49 years
- Planned cyclophosphamide-containing adjuvant/neoadjuvant chemotherapy
Cannot Have:
- Estrogen, antiestrogen, SERM, AI, or hormonal contraceptive use within 1 month
- Interest in future fertility was NOT required for enrollment
💊 Dosing Quick Guide
Experimental Regimen
Goserelin: 3.6 mg subcutaneously every 4 weeks Start: 1 week before initial chemotherapy dose Stop: Within 2 weeks before or after final chemotherapy dose Chemotherapy: Investigator's choice cyclophosphamide-containing regimen
Control Regimen
Chemotherapy alone: Investigator's choice cyclophosphamide-containing regimen
Key Dose Modifications [2]
- Per FDA labeling for goserelin; no trial-specific dose modifications reported
- Monitor for hormonal side effects (hot flashes, mood changes, menstrual irregularity)
Mechanism: Goserelin is a GnRH agonist that suppresses pituitary gonadotropin secretion, rendering ovaries quiescent and potentially less vulnerable to chemotherapy-induced damage [2].
⚠️ Safety Snapshot
| Grade 3 Toxicities | Chemo Alone (n=111) | Chemo + Goserelin (n=103) |
|---|---|---|
| Hot flashes | 3 | 4 |
| Irregular menses | 0 | 2 |
| Agitation | 1 | 0 |
| Depression | 0 | 1 |
| Joint pain | 1 | 0 |
| Headache | 1 | 0 |
| Thromboembolism (grade 4) | 0 | 1 |
Key safety metrics:
- Grade ≥3 toxic effects: 5% vs 7% (P=0.89)
- Grade ≥2 toxic effects: 24% vs 48% (P<0.001) — expected hormonal effects
Only hormonal AEs and serious AEs during chemo were routinely assessed.
📊 Key Numbers
Median follow-up: 4.1 years
| Outcome (Population) | Chemo Alone | Chemo + Goserelin | Effect (95% CI) | p-value |
|---|---|---|---|---|
| Ovarian failure at 2 yr (N=135) | 22% (15/69) | 8% (5/66) | OR 0.30 (0.09–0.97) | P=0.04 |
| Pregnancy within 5 yr (N=218) | 11% (12/113) | 21% (22/105) | OR 2.45 (1.09–5.51) | P=0.03 |
| 4-yr DFS (N=218) | 78% | 89% | HR 0.49 (0.24–0.97) | P=0.04 |
| 4-yr OS (N=218) | 82% | 92% | HR 0.43 (0.18–1.00) | P=0.05 |
| Ovarian dysfunction yr 2 (N=130) | 33% | 14% | OR 0.35 (0.13–0.93) | P=0.03 |
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| POEMS/S0230 | Chemo ± goserelin | Premenopausal, HR−, stage I–IIIA | Ovarian failure at 2 yr | OR 0.30 (P=0.04) | [1] |
| PROMISE-GIM6 | Chemo ± triptorelin | Premenopausal, HR− & HR+ | POF at 1 yr | See [4] | [4] |
| OPTION | Chemo ± goserelin | Premenopausal, HR− & HR+ | Amenorrhea at 2 yr | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
No subgroup analyses were reported in this publication. The trial closed early and was not powered for subgroup comparisons.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Goserelin approved for advanced breast cancer; ovarian protection use supported by guidelines but not a separate labeled indication [2] |
| EMA | Similar profile |
⚠️ Verify current regulatory status before prescribing.
NCCN: GnRH agonist coadministration during chemotherapy recommended for ovarian function preservation discussion in premenopausal patients [3]
ASCO: 2018 fertility preservation guideline supports GnRH agonist use for ovarian protection during chemotherapy
⚡ Grey Zones
- Only HR-negative patients enrolled — not directly applicable to HR-positive population (majority of premenopausal BC)
- Trial closed early (257 of 416 planned) — underpowered for some endpoints; wide confidence intervals
- DFS and OS benefits unexpected and based on few events — hypothesis-generating, not confirmatory
- Long-term ovarian function beyond 2 years not assessed as primary endpoint
- Generalizability to modern cyclophosphamide-free chemotherapy regimens is uncertain
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. N Engl J Med. 2015;372(10):923-932. doi:10.1056/NEJMoa1413204
- Zoladex (goserelin acetate implant) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Lambertini M, Boni L, Michelotti A, et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. JAMA. 2015;314(24):2632-2640. doi:10.1001/jama.2015.17291
- Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28(8):1811-1816. doi:10.1093/annonc/mdx184